Ms Contin (Morphine Sulfate Pentahydrate)

Morphine Sulfate, the active ingredient in Ms Contin, is an opioid analgesic presented as an extended‑release oral tablet for oral use. It treats moderate to severe pain, including chronic and cancer‑related pain, in adult patients.\n\nGNH India supplies Ms Contin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other health‑care institutions worldwide.

Ms Contin is an opioid analgesic used in the management of pain syndromes.\n\n- Moderate to severe pain: provides continuous analgesia for acute or breakthrough pain in adult patients.\n- Chronic non‑cancer pain: helps control long‑term pain where sustained relief is required.\n- Cancer‑related pain: alleviates severe pain associated with malignant disease, improving quality of life.

Common Side Effects:\n- Constipation: reduced gastrointestinal motility leading to hard stools.\n- Nausea: feeling of sickness often accompanying opioid therapy.\n- Drowsiness: sedation that may affect alertness.\n- Dry mouth: decreased salivation causing oral discomfort.\n\nSerious or Rare Side Effects:\n- Respiratory depression: slowed breathing that can be life‑threatening.\n- Severe hypotension: marked drop in blood pressure requiring medical attention.\n- Dependence or addiction: potential for misuse with prolonged exposure.

Ms Contin requires careful clinical monitoring and adherence to prescribing guidelines.\n\n- Dose titration: adjust dose gradually under medical supervision.\n- Respiratory status: monitor patients with compromised breathing function.\n- Concomitant CNS depressants: avoid or use with caution due to additive sedation.\n- History of substance abuse: assess risk before initiating therapy.\n- Pregnancy and lactation: evaluate benefits versus risks; data are limited.\n- Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Ms Contin may interact with other medicines, altering its safety or effectiveness.\n\nMajor Interactions (Avoid):\n- CNS depressants (e.g., benzodiazepines, barbiturates): increased risk of respiratory depression.\n- MAO inhibitors: risk of severe hypertension or serotonin syndrome.\n- SSRIs or SNRIs: potential for serotonin syndrome.\n\nModerate Interactions (Monitor Closely):\n- Anticholinergics: may worsen constipation.\n- Diuretics: may enhance hypotensive effect.\n- HIV protease inhibitors: may increase morphine plasma concentrations.